Parabilis Medicines, Inc.
PBLS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PBLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PBLS
Parabilis Medicines, Inc. (PBLS) is a clinical-stage biotechnology company focused on developing therapies for desmoid tumors and other rare tumors, with no approved products and a history of operating losses.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Parabilis Medicines, Inc..
Parabilis Medicines, Inc. (PBLS) is a clinical-stage biotechnology company focused on developing therapies for desmoid tumors and other rare tumors, with no approved products and a history of operating losses.
- Parabilis Medicines is a clinical-stage biotechnology company with no products approved for commercial sale [sec · filed 2026-05-19].
- As of June 30, 2026, the company had cash and equivalents of $1,089.9M, total revenue of $0.1M, and a net loss of $52.5M [sec].
- The company's lead product candidate is zolucatetide, currently in clinical trials for desmoid tumors [sec · filed 2026-05-19].
- As of June 30, 2026, Parabilis had an accumulated deficit of $639.3M [sec_mda · as of 2026-08-13].
What works
- The company has a substantial cash position of $1,089.9M as of June 30, 2026, which may support ongoing and planned clinical development [sec].
- Parabilis is advancing a lead product candidate, zolucatetide, in clinical trials for desmoid tumors, a defined patient population [sec · filed 2026-05-19].
- The company's Helicon discovery platform underpins its research and development programs, potentially enabling a pipeline of product candidates [sec · filed 2026-05-19].
What to weigh
- Parabilis has no products approved for commercial sale and has never generated revenue from product sales [sec · filed 2026-05-19].
- The company has a history of operating losses, with an accumulated deficit of $639.3M as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Clinical development is inherently risky; the company's ongoing and planned trials for zolucatetide may not be successful [sec · filed 2026-05-19].
- Parabilis will require substantial additional capital to fund its operations, and failure to raise capital could force delays or reductions in programs [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
The company has no approved products and no revenue from product sales.
“We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale”
SEC filings · May 19, 2026
The company has a significant accumulated deficit.
“As of June 30, 2026, we had an accumulated deficit of $639.3 million.”
SEC MD&A · August 13, 2026
The company expects expenses to increase substantially.
“We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue preclinical activities and studies, advance ongoing clinical trials of our product candidates and conduct future clinical trials.”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No approved products — Parabilis has no products approved for commercial sale and has never generated product revenue [sec · filed 2026-05-19].
- Clinical trial risk — The company's lead candidate, zolucatetide, may fail in clinical trials, which would materially harm the business [sec · filed 2026-05-19].
- Capital needs — Parabilis will require substantial additional capital; failure to raise funds could force program delays or cuts [sec_mda · as of 2026-08-13].
- Operating losses — The company has an accumulated deficit of $639.3M and expects losses to continue [sec_mda · as of 2026-08-13].
What to watch
- Progress of clinical trials for zolucatetide in desmoid tumors and potential expansion into other indications [sec · filed 2026-05-19].
- Updates on the company's cash runway and any future capital-raising activities [sec_mda · as of 2026-08-13].
- Regulatory developments and any filings for zolucatetide or other pipeline candidates [sec · filed 2026-05-19].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Parabilis Medicines, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Parabilis Medicines, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
66.0 months
D/E 0.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
14 buys · 0 sells (180d)
Runway
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Parabilis Medicines, Inc.?
Parabilis Medicines, Inc. (PBLS) is a clinical-stage biotechnology company focused on developing therapies for desmoid tumors and other rare tumors, with no approved products and a history of operating losses.
Who is the CEO of Parabilis Medicines, Inc.?
Dr. Mathai Mammen M.D., Ph.D. is the chief executive officer of Parabilis Medicines, Inc. (PBLS).
Where is Parabilis Medicines, Inc. headquartered?
Parabilis Medicines, Inc. (PBLS) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Parabilis Medicines, Inc. focus on?
Parabilis Medicines, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.